Wormental222/440 Fenbendazole Tablets

I. Basic Information

Generic Name: Fenbendazole

Specifications: 150 mg/tablet (100 tablets/box); 222 mg/tablet (100 tablets/box); 440 mg/tablet (100 tablets/box); 500 mg/tablet (100 tablets/box)

Manufacturer: Kachhela Medex Pvt Ltd

II. Indications

1. Antiparasitic Action

Nematode/Cestode Infections: Eliminates adult and larval parasites by inhibiting the polymerization of parasitic tubulin and blocking energy metabolism.

Case Studies: Isolated reports exist regarding its use for human intestinal parasitic infections; however, supporting clinical data is currently lacking.

2. Antitumor Action

Small Cell Lung Cancer (SCLC):

Mechanism: Disrupts the microtubule structure of cancer cells, induces oxidative stress, inhibits glycolysis, and activates the p53 pathway to promote apoptosis.

Combination Therapy: Concurrent use with cisplatin or immune checkpoint inhibitors (e.g., PD-L1 inhibitors) may enhance therapeutic efficacy.

Other Cancers: *In vitro* studies suggest potential inhibitory effects against breast cancer, colon cancer, and other malignancies.

III. Unofficial Treatment Protocols

Standard Protocols:

"222 Protocol": 222 mg daily for 5–7 consecutive days, followed by a 2–3 day break (cycled).

"444 Protocol": 444 mg daily for 5–7 consecutive days, followed by a 2–3 day break (cycled).

"500 Protocol": 500 mg daily for 5–7 consecutive days, followed by a 2–3 day break (cycled).

High-Fat Diet Adjuvant: Administer concurrently with olive oil or coconut oil to enhance bioavailability (by approximately 10%).

Combination Therapy:

Chemotherapy: Used in combination with cisplatin or etoposide to augment cytotoxicity.

Metabolic Intervention: Used in combination with metformin to inhibit glycolysis.

IV. Adverse Reactions and Risks

Common Reactions:

Gastrointestinal: Nausea, diarrhea, and abdominal pain (incidence: approximately 5%).

Hepatotoxicity: Elevated transaminase levels (ALT/AST); regular monitoring of liver function is required. Serious Risks:

Bone Marrow Suppression: Neutropenia, thrombocytopenia (reported in isolated cases).

Allergic Reactions: Rash, angioedema (rare).

V. Contraindications and Precautions

Contraindicated Populations:

• Pregnant women (animal studies have demonstrated embryotoxicity).

• Patients with severe hepatic impairment.

Precautions:

Drug Interactions: Avoid concomitant use with cimetidine (which increases plasma drug concentrations) or anticoagulants.

Risk of Parasite Migration: Severe parasitic infections may precipitate intestinal obstruction; therefore, deworming should be performed in a staged manner.

VI. Current Research Status and Challenges

Level of Evidence:

Laboratory Data: *In vitro* studies and animal models suggest potential anticancer activity, but this lacks validation through Phase III clinical trials.

Bioavailability: Oral absorption is low (approximately 10%); optimization via lipid-based carriers or nan formulations is required.

Safety Concerns: Long-term use may induce drug resistance and lead to unknown adverse effects.

Summary: While fenbendazole demonstrates proven efficacy in the treatment of parasitic infections, its application in humans remains in an exploratory phase. Although its potential as an anticancer agent has garnered attention, it lacks clinical validation and carries extremely high risks. Patients must strictly weigh the benefits against the risks under the guidance of an oncologist and should never self-medicate.